Effectiveness and safety of filgotinib in rheumatoid arthritis: a real-life multicentre experience.

Autor:	La Barbera L; Rheumatology Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Italy., Rizzo C; Rheumatology Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Italy., Camarda F; Rheumatology Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Italy., Atzeni F; Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, Italy., Miceli G; Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, Italy., Molica Colella AB; Rheumatology Unit, Azienda Ospedaliera Papardo, Messina, Italy., Franchina V; Medical Oncology Unit, Azienda Ospedaliera Papardo, Messina, Italy., Giardina A; Internal Medicine Department iGR, National Relevance Hospital Trust, ARNAS Civico, Di Cristina e Benfratelli, Palermo, Italy., Corrao S; Internal Medicine Department iGR, National Relevance Hospital Trust, ARNAS Civico, Di Cristina e Benfratelli, Palermo, Italy., Provenzano G; Rheumatology Unit, Villa Sofia-Cervello Hospital, Palermo, Italy., Bursi R; Rheumatology Unit, Villa Sofia-Cervello Hospital, Palermo, Italy., Foti R; Rheumatology Unit, Vittorio-Emanuele Hospital, Catania, Italy., Dal Bosco Y; Rheumatology Unit, Vittorio-Emanuele Hospital, Catania, Italy., Debilio C; Rheumatology Unit, Department of Medicine, Sant'Antonio Abate Hospital, Trapani, Italy., Luppino F; Rheumatology Unit, Department of Medicine, Sant'Antonio Abate Hospital, Trapani, Italy., Colaci M; Unit of Internal Medicine and Hypertension Centre, Department of Clinical and Experimental Medicine, University of Catania, Cannizzaro Hospital, Catania, Italy., Aprile ML; Unit of Internal Medicine and Hypertension Centre, Department of Clinical and Experimental Medicine, University of Catania, Cannizzaro Hospital, Catania, Italy., Bentivegna M; Integrated Reference Centre of Rheumatology, ASP 7, Scicli Hospital, Ragusa, Italy., Cassarà E; Integrated Reference Centre of Rheumatology, ASP 7, Scicli Hospital, Ragusa, Italy., Lo Gullo A; Unit of Rheumatology, Department of Medicine, ARNAS Garibaldi Hospital, Catania, Italy., De Andres MI; Unit of Rheumatology, Department of Medicine, ARNAS Garibaldi Hospital, Catania, Italy., Guggino G; Rheumatology Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Italy. giuliana.guggino@unipa.it.
Jazyk:	angličtina
Zdroj:	Clinical and experimental rheumatology [Clin Exp Rheumatol] 2024 May; Vol. 42 (5), pp. 991-998. Date of Electronic Publication: 2024 Jan 08.
DOI:	10.55563/clinexprheumatol/k78ug3
Abstrakt:	Objectives: We investigated the effectiveness and safety of filgotinib in a real-life multicentre cohort of rheumatoid arthritis (RA) patients. Methods: RA patients were evaluated at baseline and after 12 and 24 weeks and were stratified based on previous treatments as biologic disease-modifying anti-rheumatic drug (bDMARD)-naive and bDMARD-insufficient responders (IR). Concomitant usage of methotrexate (MTX) and oral glucocorticoids (GC) was recorded. At each timepoint we recorded disease activity, laboratory parameters and adverse events. Results: 126 patients were enrolled. 15.8% were bDMARD-naive (G0), while 84% were bDMARD-IR (G1). In G0, 45% of patients were in monotherapy (G2) and 55% were taken MTX (G3). In G1, 50% of patients were in monotherapy (G4) and 50% used MTX (G5).A significant reduction in all parameters at 12 weeks was observed; in the extension to 24 weeks the significant reduction was maintained for patient global assessment (PGA), examiner global assessment (EGA), visual analogue scale (VAS) pain, VAS fatigue, disease activity score (DAS)28- C-reactive protein (CRP) and CRP values. Filgotinib in monotherapy showed better outcomes in bDMARD-naive patients, with significant differences for patient reported outcomes (PROs) and DAS28-CRP. At 12 weeks, low disease activity (LDA) and remission were achieved in a percentage of 37.2 % and 10.7 % by simplified disease activity index (SDAI), 42.6 % and 5.7 % by clinical disease activity index (CDAI), 26.8 % and 25.2 % by DAS28-CRP, respectively. A significant decrease in steroid dose was evidenced in all patients. We observed a major adverse cardiovascular event in one patient and an increase in transaminase in another. No infections from Herpes Zoster were reported. Conclusions: Our real-world data confirm the effectiveness and safety of filgotinib in the management of RA, especially in bDMARD-naive patients.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu